The Company does not intend to invest in the clinical development of SENTI-301A, for the treatment of hepatocellular carcinoma (HCC), on its own at this time; however, the Company believes there is significant market opportunity for SENTI-301A, especially in territories within Asia where HCC is more prevalent than in the United States. Accordingly, the Company is actively pursuing strategic geographic partnerships for clinical development of SENTI-301A
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNTI:
- Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
- Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
- Senti Bio initiated with a Neutral at JPMorgan
- Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
